Early identification of androgen receptor gene amplification and prostate cancer risk

Historically, it has generally been assumed that androgen receptor gene amplification was a result of androgen deprivation therapy (ADT) and occurred in some 20 to 30 percent of men with castration-resistant prostate cancer (CRPC). However, … READ MORE …

AR gene amplification and risk for CRPC

An article just published in the British Journal of Cancer, has proposed that androgen receptor (AR) gene amplification may be a prime cause of treatment failure in a subset of men with progressive prostate cancer. … READ MORE …